$177 Million is the total value of Stonepine Capital Management, LLC's 21 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 44.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VIVE | Buy | Viveve Medical, Inc | $24,256,000 | +82.4% | 3,849,711 | +48.1% | 13.67% | +72.6% |
| NVLNF | Buy | Novelion Therapeutics, Inc. | $16,760,000 | +30.6% | 1,560,487 | +2.4% | 9.44% | +23.6% |
| SCLN | Buy | Sciclone Pharmaceuticals, Inc. | $16,300,000 | +20.8% | 1,663,281 | +33.1% | 9.19% | +14.3% |
| OPHT | Buy | Ophthotech Corp | $12,870,000 | +16.2% | 3,516,489 | +53.4% | 7.25% | +9.9% |
| VCEL | Buy | Vericel Corp | $9,143,000 | +61.8% | 3,265,323 | +73.3% | 5.15% | +53.1% |
| AVDL | New | Avadel Pharmaceuticals PLCspons adr | $7,283,000 | – | 752,410 | +100.0% | 4.10% | – |
| BDSI | Buy | Biodelivery Sciences INTL | $5,405,000 | +18.8% | 2,844,820 | +9.4% | 3.05% | +12.4% |
| CPIX | Buy | Cumberland Pharmaceuticals, Inc. | $5,135,000 | +50.7% | 739,917 | +19.4% | 2.89% | +42.6% |
| DRRX | Buy | Durect Corporation | $2,941,000 | +0.8% | 2,801,376 | +28.6% | 1.66% | -4.7% |
| EBS | New | Emergent Biosolutions Inc | $1,583,000 | – | 54,505 | +100.0% | 0.89% | – |
| XOMA | New | XOMA CORP | $625,000 | – | 87,960 | +100.0% | 0.35% | – |
| VNDA | New | VANDA PHARMACEUTICALS INC | $606,000 | – | 43,300 | +100.0% | 0.34% | – |
| AVIR | Buy | Aviragen Therapeutics, Inc. | $205,000 | -46.1% | 314,421 | +1.7% | 0.12% | -48.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 23 | Q2 2024 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| EVOLUS INC | 14 | Q2 2024 | 29.7% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| EXAGEN INC | 14 | Q2 2024 | 4.6% |
| ADMA BIOLOGICS INC | 13 | Q2 2024 | 19.2% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DE | April 19, 2024 | 199,158 | 6.0% |
| ALIMERA SCIENCES INC | February 13, 2024 | 5,373,732 | 10.0% |
| aTYR PHARMA INC | February 13, 2024 | 482,258 | 0.8% |
| AYTU BIOPHARMA, INC | February 13, 2024 | 565,484 | 10.0% |
| DELCATH SYSTEMS, INC. | February 13, 2024 | 208,333 | 0.9% |
| Evolus, Inc. | February 13, 2024 | 5,333,004 | 9.3% |
| EXAGEN INC. | February 13, 2024 | 669,684 | 3.9% |
| Gamida Cell Ltd. | February 13, 2024 | 3,000,000 | 2.2% |
| IO Biotech, Inc. | February 13, 2024 | 3,641,345 | 5.4% |
| Rezolute, Inc. | February 13, 2024 | 2,768,656 | 7.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-26 |
| 13F-HR/A | 2024-08-21 |
| SC 13G | 2024-08-15 |
| 13F-HR | 2024-08-13 |
| SC 13G | 2024-07-29 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.